21st Jan 2022 14:36
Destiny Pharma PLC - clinical-stage biotechnology company based in Brighton, England - Notes a "major" Lancet study that highlighted that over 1 million deaths in 2019 occurred due to bacterial antimicrobial resistance. Study states that antimicrobial resistance is one of the leading causes of death around the world.
Says that this demonstrates the clinical need and potential global commercial opportunity for its XF platform. Explains that the XF platform has been shown not to generate antimicrobial resistance in published studies.
Says that it is currently in advanced discussions with regulatory authorities in Europe and the US to clarify the design, size and costs of the final Phase 3 clinical trials needed for registration. Expects to receive feedback from the European Medicines Authority in the first quarter this year. Feedback from the US Food & Drug Administration is expected during the second quarter.
Current stock price: 102.30 pence
12-month change: down 9.5%
By Abby Amoakuh; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
DEST.L